Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BOTOX Treatment in Pediatric Upper Limb Spasticity: Open-label Study

Trial Profile

BOTOX Treatment in Pediatric Upper Limb Spasticity: Open-label Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Muscle spasticity
  • Focus Adverse reactions; Registrational
  • Sponsors Allergan
  • Most Recent Events

    • 21 Jun 2019 According to an Allergan media release, the company announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics application (sBLA) for BOTOX for the treatment of pediatric patients (2 to 17 years of age) with upper limb spasticity.This approval is based on data from two Phase 3 studies included a 12-week, double-blind study and a one-year open label extension study.
    • 07 Mar 2019 According to an Allergan media release, the company announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license applications (sBLAs) to expand the onabotulinumtoxinA label for the treatment of pediatric patients (2 years of age and older) with upper and lower limb spasticity. sBLA submissions are based on data from four Phase 3 studies.
    • 10 Oct 2018 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top